FierceBiotech |
Merck finally ditches osteoporosis drug odanacatib after stroke risk
FierceBiotech Two years ago the Big Pharma announced it was to delay a filing with the FDA after Phase III results showed that while the drug could reduce fractures, it also increased the risk of atrial fibrillation and stroke. It had hoped for a 2015 U.S. approval … Merck Halts Development of Osteoporosis Drug Due to Stroke Risk Merck scraps development of osteoporosis drug due to stroke risk Increased stroke risk prompts Merck to pull the plug on osteoporosis … |
4
SEP
SEP
0